A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t HHS Public Access Author manuscript Cell Rep Author manuscript available PMC 2019 September 03 Published final edited form Cell Rep 2019 April 16 273 806819e5 doi101016jcelrep201903066 Pulsatile MEK Inhibition Improves Antitumor Immunity T Cell Function Murine Kras Mutant Lung Cancer Hyejin Choi110 Jiehui Deng310 Shuai Li310 Tarik Silk1 Lauren Dong1 Elliott J Brea49 Sean Houghton1 David Redmond1 Hong Zhong1 Jonathan Boiarsky1 Esra A Akbay56 Paul D Smith7 Taha Merghoub128911 KwokKin Wong3 Jedd D Wolchok1289 1Ludwig Collaborative Swim Across America Laboratory Memorial Sloan Kettering Cancer Center New York NY 10065 USA 2Parker Institute Cancer Immunotherapy Memorial Sloan Kettering Cancer Center New York NY 10065 USA 3Division Hematology Medical Oncology Laura Isaac Perlmutter Cancer Center New York University Langone Medical Center New York NY 10016 USA 4Molecular Pharmacology Chemistry Program Sloan Kettering Institute New York NY 10065 USA This open access article CC BYNCND license httpcreativecommonsorglicensesBYNCND40 Correspondence merghoutmskccorg TM kwokkinwongnyumcorg KKW wolchokjmskccorg JDW AUTHOR CONTRIBUTIONS Conceptualization HC JD SL PDS KKW TM JDW Validation HC JD SL LD HZ Formal Analysis HC JD SL SH DR Investigation HC JD SL TS EJB JB Writing Original Draft HC JD SL Writing Review Editing HC JD SL TS EAA TM JDW Visualization HC JD SL Supervision TM JDW KKW SUPPLEMENTAL INFORMATION Supplemental Information online httpsdoiorg101016jcelrep201903066 DECLARATION OF INTERESTS PDS employee shareholder AstraZeneca TM cofounder holds equity IMVAQ Therapeutics He consultant Immunos Therapeutics Pfizer He research support BristolMyers Squibb Surface Oncology Kyn Therapeutics Infinity Pharmaceuticals Inc Peregrine Pharmeceuticals Inc Adaptive Biotechnologies Leap Therapeutics Inc Aprea He patents applications related work oncolytic viral therapy alpha virusbased vaccine neo antigen modeling CD40 GITR OX40 PD1 CTLA4 KKW founder equity holder G1 Therapeutics He sponsored research agreements MedImmune Takeda TargImmune BMS He consulting sponsored research agreements AstraZeneca Janssen Pfizer Novartis Merck Ono Array JDW consultant Adaptive Biotech Advaxis Amgen Apricity Array BioPharma Ascentage Pharma Astellas Bayer Beigene Bristol Myers Squibb Celgene Chugai Elucida Eli Lilly F Star Genentech Imvaq Janssen Kleo Pharma Linneaus MedImmune Merck Neon Therapuetics Ono Polaris Pharma Polynoma Psioxus Puretech Recepta Trieza Sellas Life Sciences Serametrix Surface Oncology Syndax He research support Bristol Myers Squibb Medimmune Genentech He holds equity Potenza Therapeutics Tizona Pharmaceuticals Adaptive Biotechnologies Elucida Imvaq Beigene Trieza Linneaus honorarium Esanex He patents xenogeneic DNA vaccines royalties alphavirus replicon particles expressing TRP2 myeloidderived suppressor cell MDSC assay royalties Newcastle disease viruses cancer therapy genomic signature identify responders ipilimumab melanoma engineered vaccinia viruses cancer immunotherapy antiCD40 agonist monoclonal antibody mAb fused monophosphoryl lipid A MPL cancer therapy CAR T cells targeting differentiation antigens means treat cancer antiPD1 antibody antiCTLA4 antibodies antiGITR antibodies methods use thereof The authors declare competing interests Data Resources GSE12620 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 2 5Department Pathology University Texas Southwestern Medical Center Dallas Dallas TX 75390 USA 6Simmons Comprehensive Cancer Center Dallas TX 75390 USA 7Bioscience iMed Oncology AstraZeneca CRUK Cambridge Institute Cambridge CB2 0RE UK 8Department Medicine Memorial Sloan Kettering Cancer Center New York NY 10065 USA 9Weill Cornell Medicine New York NY 10065 USA 10These authors contributed equally 11Lead Contact SUMMARY KRAS driver oncogenes nonsmallcell lung cancer NSCLC remains refractory current modalities targeted pathway inhibition include inhibiting downstream kinase MEK circumvent KRAS activation Here pulsatile continuous treatment MEK inhibitors MEKis maintains T cell activation enables proliferation Two MEKis selumetinib trametinib induce T cell activation increased CTLA4 expression lesser extent PD1 expression T cells vivo cyclical pulsatile MEKi treatment In addition pulsatile dosing schedule shows superior anti tumor effects delays emergence drug resistance Furthermore pulsatile MEKi treatment combined CTLA4 blockade prolongs survival mice bearing tumors mutant Kras Our results set foundation importance combinatorial therapeutic strategy pulsatile targeted therapy immunotherapy optimally enhance tumor delay promote longterm antitumor immunity Graphical Abstract In Brief Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 3 KRAS mutant nonsmallcell lung cancer NSCLC remains refractory targeted therapeutics Choi et al pulsatile continuous treatment MEK inhibitors maintain T cell activity better prolong survival mice Kras mutant cancer This effect enhanced combined CTLA4 blockade INTRODUCTION The RASMEKERK signaling pathway hyperactivated variety different cancers including nonsmallcell lung cancer NSCLC Fern√°ndezMedarde Santos 2011 Activating mutations KRAS common oncogenic drivers responsible 2030 lung adenocarcinoma patients Lovly Carbone 2011 However currently approved targeted therapies specifically NSCLC patients KRAS mutation Targeted MEK inhibitors MEKis act downstream RAS signaling pathway designed block hyperactive signaling cascade KRAS mutant lung cancer patients Ostrem et al 2013 Zeng et al 2017 block proliferation survival program cancer cells Riely et al 2009 MEKis diverse phases clinical development including trametinib approved combination BRAF inhibitor dabrafenib treatment subset NSCLC BRAFV600E mutation Friday Adjei 2008 Greystoke et al 2017 Planchard et al 2017 Stinchcombe Johnson 2014 However despite promising coclinical studies mouse models clinical trials Chen et al 2012 Greystoke et al 2017 Planchard et al 2017 resistance MEKis observed Soria et al 2017 This resistance attributed heterogeneity tumor JamalHanjani et al 2017 Swanton Govindan 2016 intrinsic acquired resistance cancer cells tumor microenvironment Ebert et al 2016 Manchado et al 2016 Therefore need improve efficacy MEKis KRASdriven lung cancer A theoretically promising therapeutic approach entail simultaneously blocking KRAS signaling activating tumorinfiltrating T cells relevant given recent demonstration activity immune checkpoint blockade CTLA4 PD1 pathways NSCLC malignancies Borghaei et al 2015 Brahmer et al 2015 Garon et al 2015 Reck et al 2016 Wolchok et al 2013 Despite success immunebased therapies need remains better treatment strategies majority patients advanced NSCLC response current singleagent PD1 pathway blockade durable subset patients Borghaei et al 2015 Brahmer et al 2015 initial results combination CTLA4 blockade showed promising efficacy treatment NSCLC subset patients Hellmann et al 2017 Based limitations immunebased therapies targeted therapies sought rationally combine modalities treat KRAS mutant lung cancers In addition essential role MEKis RASMEKERK signaling suppression tumorigenesis NSCLC effect MEKis immune cells complex context dependent The RASMEKERK signaling cascade critical normal physiologic function immune cells especially T cells Weiss Littman 1994 The sequential signaling RASMEKERK T cell receptor TCR activation responsible Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 4 activity NFAT production interleukin IL2 critical T cell clonal expansion Kane et al 2000 Weiss Littman 1994 Previous studies shown inhibition MEK signaling small molecules reduces regulates paradoxically proliferation T cells vitro Callahan et al 2014 Liu et al 2015a Nevertheless enhances proliferation tumorinfiltrating CD8 T cells CT26 Kras mutant colorectal cancer resulting expansion tumorreactive T cell populations cytotoxic activity Ebert et al 2016 Liu et al 2015a However conventional continuous administration MEKis achieves inadequate inhibition ERK activity induces feedback regulation proliferation survival pathways reactivates MEKERK signaling leading drug resistance Samatar Poulikakos 2014 Sun et al 2014 Moreover prolonged blockade TCR signaling MEKis interferes effector function proliferation tumor site Dushyanthen et al 2017 The recent failure clinical trial continuous MEKi cobimetinib antiPDL1 atozolizumab combination treatment colorectal cancer phase III IMblaze370 study NCT02788279 suggests scheduling drugs needs optimization Unconventional pulsatile treatment schedules targeted drugs BRAF inhibitor vemurafenib EGFR inhibitor gefitinib showed better suppression tumor growth melanoma breast cancer leukemia Das Thakur et al 2013 Shah et al 2008 Solit et al 2005 In support pulsatile treatment regimen case MEKis transient pretreatment leadin treatment MEKis combination antiCTLA4 antiPD1 showed better survival lower tumor burden CT26 mouse tumor model Poon et al 2017 Despite encouraging observations status T cell activation unconventional regimens explored systematically We hypothesize optimized MEKi dosing schedule maximize suppression KRASinduced proliferation survival cancer cells minimizing detrimental effects immune cells In study investigated pulsatile dosing schedule MEKis affects T cell activation mutant KRASdriven lung cancer models ex vivo vivo We observed pulsatile treatment induced improved proliferation activation T cells higher expression levels immune checkpoint regulators including CTLA4 PD1 compared conventional continuous treatment drug This optimized schedule pulsatile treatment resulted delayed tumor growth KRAS mutant genetically engineered mouse models GEMMs Furthermore combination pulsatile MEKis CTLA4 blockade resulted prolonged survival mice KRAS mutant lung cancer compared continuous treatment MEKis combination antiCTLA4 RESULTS MEK Inhibition Affects Tumor Growth Kras Mutant Lung Cancer MAPK Signaling Both Tumor Cells T Cells We treated Kras mutant murine lung cancer cell lines CL13 CL25 IO33 HKP1 LLC selumetinib trametinib examine sensitive clinically relevant MEKis The HKP1 cell line derived KrasG12D Trp53 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 5 mouse Choi et al 2015 We characterized mutations IO33 CL13 CL25 LLC cell lines identified G12V Q61R Q61H G12C Kras mutations respectively Figure S1A We observed MEKis block phosphorylation ERK Kras mutant cells effectively Figure 1A tumor cells reduced viability treatment Figure 1B Furthermore selumetinib extends survival HKP1 lung tumorbearing mice suggesting cytotoxic activity Kras mutant lung cancer vivo Figure 1C When characterized T cells decreased viability reduced pERK CD8 T cells CD4 T cells Figures 1D S1B We observed increased interferon IFNŒ≥ expression lunginfiltrating CD8 T cells CD4 T cells vivo selumetinib treatment Figure S1C suggests differential regulation MEKis distinct immune cell populations Taken data confirm MEKis dampen signaling ERK pathway tumor cells T cells combining MEKis immune modulation carefully respect timing Short Pulsatile Not Long Continuous Treatment MEKis Activates T Cells Ex Vivo To investigate short treatment MEKis affect T cell activation treated splenocytes HKP1 lung tumorbearing mice vitro selumetinib trametinib long short schedule activating T cells antiCD3 antiCD28 Figure 2A Figure S2 Treatment selumetinib trametinib reduced expression Ki67 41BB CTLA4 PD1 T cells dosedependent manner Figure 2B However short schedule treatment maintained Ki67 41BB CTLA4 PD1 better CD8 T cells CD4Foxp3 effector T cells compared long drug exposure Figures 2B S2 This suggests short treatment MEKis maintain T cells activated state continuous treatment Short Treatment MEKis Increases Effector T Cell Priming Since shown previously MEKi cobimetinib reduces priming T cells lymph nodes Ebert et al 2016 tested short treatment MEKis affects priming antigenspecific Pmel1 CD8 T cells Splenocytes Pmel1 TCR transgenic mice pulsed gp100 Pmel peptide treated selumetinib trametinib Figure 3A We MEKi treatment reduced differentiation Pmel1 CD8 T cells decreasing Tbet expression dosedependent manner Figure S3A previously reported Ebert et al 2016 However observed differences Tbet expression treatment groups Figure S3A Selumetinib trametinib treatment resulted increased CD44CD62L effector memory CD8 T cells reduced CD44CD62L central memory CD8 T cells compared untreated samples Figures 3B 3C However short treatment MEKis showed CD44 cells specifically CD44CD62L CD8 T cells compared long treatment Figures 3B3D Interestingly CD44CD62L CD8 T cells naive cells showed decreased proliferation selumetinib treatment groups CD44CD62L CD8 T cells showed proliferative phenotype compared subsets regardless treatment conditions Figure S3B Furthermore analysis supernatant priming showed short treatment group higher production IFNŒ≥ suggesting better cytolytic capability Figure 3E Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 6 Pulsatile Treatment MEKis Increases CTLA4 PD1 Expression Tumor Infiltrating T Cells compared Continuous Treatment Next investigated cyclical pulsatile treatment MEKis shows differential activation different subtypes T cells vivo We treated HKP1 lung tumorbearing mice selumetinib Figure 4A After 2 weeks treatment lung tumors analyzed activation phenotype tumorinfiltrating T cells Tumors highly infiltrated CD8 T cells pulsatile treatment groups Figures 4B S4C More importantly tumor cells CD8 T cells showed differential proliferation Ki67 pulsatile treatment While proliferation tumor cells reduced CD8 T cells showed increased stable proliferation Figure 4C These observations suggest individual T cell populations respond MEKi treatment differently Furthermore pulsatile treatment selumetinib results maintenance higher level pERK CD8 CD4 T cells compared continuous treatment Figure S4 suggesting reduced suppression MEK signaling pathways pulsatile treatment T cells Consistent ex vivo observations CTLA4 PD1 expression CD8 T cells significantly higher pulsatile treatment Figure 4D Additionally PD1 showed significant increase CD4 T cells CD4Foxp3 CD4Foxp3 slight increase CD8 T cells Figure 4D We observed similar results pulsatile MEKi treatment higher doses longer lag time Figures S4BS4D Tbet expression higher pulsatile treatment CD4 T cells CD8 T cells lung tumors Figure S4C Many costimulatory markers increased regulatory T cell Treg cell population CD4 T cells CD8 T cells indicating differential regulation subsets T cells pulsatile treatment Figure S4D Collectively observations indicate pulsatile treatment MEKi establish tumor microenvironment suppresses tumor growth maintaining optimal CD8 activation infiltration tumor microenvironment Pulsatile MEKi Treatment Delays Tumor Growth In Vivo We tested pulsatile treatment confers better antitumor activity compared continuous dosing We KrasG12D mutated HKP1 transplantable tumor model Though transient delay tumor growth Figure S4E observe differences tumor progression survival pulsatile continuous treatment groups settings Figure S4F The absence differential effects highly aggressive nature transplantable tumors In order investigate effects MEKi treatment regimens utilized KRASG12C GEMM autochthonous model slower tumor progression rate allows better therapeutic window Intranasal instillation adenovirus CRE recombinase expression similarly induces lung tumor formation endogenous KrasG12D lung cancer GEMM model previously reported Chen et al 2012 Given similarity data selumetinib trametinib focused experiments MEKi selumetinib GEMM experiments After mice developed lung tumors group mice treated continuously selumetinib similar baseline tumor volumes Figure 5A Figures S5A S5B In week treatment mice responded MEKi tumor sizes started decrease quantified MRI imaging Figure 5B In second week 50 mice developed resistance treatment Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 7 tumors regrew Figure 5B Figure S5B This consistent prior work Li et al 2018 In contrast treated mice selumetinib following cyclical pulsatile schedule 1 week 1 week Figure 5A tumors continued respond MEKi reduced tumor volume untreated control tumors continued grow Figure 5C Figure S5B Both continuous pulsatile treatment groups showed decreased levels pERK tumor cells compared control group continuous group lowest pERK expression Figure 5D Supporting pERK suppression MEK signaling activation gene signature Brant et al 2017 showed consistent suppression MEK signaling pathway majority samples pulsatile continuous groups Figure S5C Overall mice treated pulsatile selumetinib significantly prolonged progressionfree survival compared treated continuous selumetinib vehicle control Figure 5E Pulsatile Treatment Induces Antitumor Immunity T Cells To understand potential contribution T cells observed antitumor effect analyzed lungs KRASG12C GEMMs end treatment selumetinib continuous pulsatile schedule Figure 5A The percentage tumor infiltrating T lymphocytes including CD4 T cells CD8 T cells significant differences total infiltrating CD45 leukocytes Figure 6A The percentage Treg cells increased continuous pulsatile selumetinib treatment However correlated tumor volume changes pulsatile continuous dosing schedule Figures 5B 5C 6A suggesting Tregs play major role setting treatment schedules gave different responses despite increase Tregs conditions At end pulsatile selumetinib treatment observed increased levels CTLA4 CD4 CD8 T cells Figure 6D Figure S6A Although PD1 levels slightly increased pulsatile treatment group difference control treated groups statistically significant Figure 6D Figure S6A On hand end continuous treatment selumetinib PD1 expression decreased CD4 CD8 T cells CTLA4 downregulated CD8 T cells determined percentage median fluorescence intensity MFI Figures 6B 6C S6A The expression levels PD1 CTLA4 high Treg cells After pulsatile treatment selumetinib expression levels PD1 CTLA4 remained unchanged Figure S6B In contrast continuous selumetinib treatment reduced CTLA4 PD1 levels Tregs Figure S6B The coinhibitory molecules LAG3 TIM3 major expression level changes CD4 CD8 T cells treatment schedule Figures 6C 6D Additionally pulsatile treatment selumetinib showed trend increased CD69 Ki67 expression indicating T cells modestly activated pulsatile treatment Figure S6C Continuous selumetinib treatment decrease PDL1 expression CD11b myeloid cells increase expression CD8 T cells Pulsatile selumetinib treatment significantly downregulated PDL1 levels EpCAM CD11b CD4 T cells Figure S6D Neither pulsatile continuous treatment affected infiltration CD11b myeloid populations significantly Figure S6E Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 8 Taken data pulsatile MEKi treatment results improved activation tumorinfiltrating T cells Interestingly higher doses 10fold selumetinib pulsatile schedule vivo Figure 7A evident detrimental effect immune terms T cell frequency PDL1 expression Figure 7B T cells activated 3 days treatment stopped determined Ki67 CTLA4 expression CD8 T cells Figures 7B 7C In addition highdose pulsatile treatment selumetinib restrain proliferation T cells Figure 7B Combination Therapy Pulsatile MEKis CTLA4 Blockade Enhances Survival Mice Kras Mutated Lung Tumors Based aforementioned observations combined CTLA4 blockade pulsatile selumetinib treatment investigate enhanced T cell activation associated pulsatile schedule produce better outcome combination checkpoint blockade tumorbearing mice We chose high concentration selumetinib pulsatile treatment proliferation CTLA4 expression elevated previous experiments Figures 7B 7C tested transplantable LLC model Kras mutation GEMM We combination pulsatile high doses selumetinib 3day gap CTLA4 blockade provided longest survival mice compared monotherapies combination therapies Figures 7D 7E The survival advantage lost Rag mice deficient T B cells Figures 7F 7G suggesting adaptive immunity contributes improved survival treatment setting Interestingly MEKis combined PD1 targeting improve survival Figure S7A In addition contribution adaptive immune cells MEKi treatment observed potential contribution NK cells survival MEKi treatment groups Figures S7B S7C Although survival difference antiCTLA4 combination modest experimental settings results bring forth possibility combination CTLA4 blockade pulsatile MEKi considered clinical trials treatment strategy KRAS mutated lung cancers DISCUSSION In study demonstrated opposed conventional continuous MEKi treatment clinic pulsatile schedule MEKi treatment effective controlling tumor progression enhancing T cell activation increased levels CTLA4 PD1 expression In comparison continuous treatment ex vivo pulsatile treatment T cells MEKis selumetinib trametinib alongside activation antiCD3 antiCD28 antibodies resulted increased CTLA4 expression lesser extent PD1 expression Concurrent changes Ki67 41BB suggest CD8 T cells CD4Foxp3 effector cells activated pulsatile treatment MEKis While changes CD4Foxp3 effector cells CD4Foxp3 T cells subtle CD8 T cells showed high expression levels immune checkpoint regulators costimulatory markers This fact CD8 T cells CD4 T cells regulated distinct signaling pathways varying dependence mitogenactivated protein MAP kinase pathway In CD8 T cells MEK¬ΩERK¬Ω signaling Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 9 critical cytotoxic activity proliferation survival Rinc√≥n et al 2001 DSouza et al 2008 In CD4 T cells MEK467p38 JNK important activity development Rinc√≥n et al 2001 This differential dependency distinct signaling pathways regulate responses CD8 T cells CD4 T cells MEKis different fashion In addition changes T cells MEKi increases major histocompatibility complex class I MHC I expression essential cytotoxic T cell activation tumor cells Brea et al 2016 In preliminary data observed increase H2Kb MHC I expression CD45 cell population pulsatile MEK inhibition HKP1 lung tumors However 23 day washout period MHC I expression decreased gradually levels untreated tumors data shown These data underscore importance timing MEKi treatment combination approaches designed Our vivo data pulsatile MEKis transplantable Kras model consistent ex vivo observations The effects pulsatile MEKi treatment pronounced CD8 T cells infiltrating tumors expression CTLA4 PD1 In vivo T cells treated preselected opposed ex vivo cells come anatomical location result speculate cells exposed MEKis different stages T cell development vivo It shown previously MEKERK pathway fundamental T cell lineage commitment thymus development Genetic reduction ERK induces CD8 cells CD4 CD8 doublepositive T cells loss CD4 markers thymus Rinc√≥n et al 2001 While pERK reduction preferable CD8 expansion thymus pERK positively regulates CD8 T cell proliferation survival IL2 cytokine expression CD8 cells Rinc√≥n et al 2001 DSouza et al 2008 Furthermore activation MEKERK signaling downregulates apoptosis activated primary peripheral T cells Holmstr√∂m et al 2000 Thus speculate pulsatile MEKis CD8 cells generated thymus treatment following period MEKis treatment allow proliferation reduce apoptosis differentiated CD8 cells globally resulting expansion CD8 populations tumor Considering intricate role ERK CD8 T cells development activation survival ERK signaling best modulated rationally designed schedule order maximize frequency activation CD8 T cells Our pulsatile schedule treatment demonstrates better control signaling pathway increasing frequency CD8 T cells expression activation markers immunotherapy targets Kras mutated lung tumors MEK inhibition tumorbearing mice previously reported interfere priming T cells lymph node enhance CD8 T cell expansion CT26 tumor site reduced apoptosis Ebert et al 2016 To test pulsatile MEKi treatment improve antigenspecific priming T cells utilized antigenspecific Pmel1 transgenic CD8 T cells pulsed gp100 peptide We showed selumetinib trametinib reduced antigenspecific activation CD44 dosedependent manner continuous pulsatile treatments suggests critical role pERK CD8 T cell priming However pulsatile MEKi treatment resulted CD44CD62L cells continuous treatment This observation important suggests pulsatile Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 10 treatment leads maintained activation compared conventional MEKi treatment To clearly understand effects MEKis immune priming future work dynamically monitor pERK expression T cell activation marker changes diverse types MEKis pulsation needed Additionally vivo studies confirming pulsatile schedule MEKis enhances priming T cells need pursued Given observations T cell phenotypic changes ex vivo vivo transplantable models evaluated changes GEMM harboring human KRASG12C mutation prevalent mutation detected NSCLC patients We pulsatile treatment MEKis superior antitumor effect delayed drug resistance comparison continuous treatment Consistent ex vivo vivo transplantable model studies tumorinfiltrating T cells showed increased CTLA4 modest upregulation PD1 levels greater proliferation activation In contrast treated KRASG12C mutant GEMM mice MEKis continuously observed reduced CTLA4 PD1 Considering tumor cells exposed equal amounts MEKis confirms activated T cells resulting pulsatile MEKi treatment enhance antitumor immunity KRASdriven lung cancer In conditions ex vivo vivo GEMM transplantable models observed pulsatile MEKi treatment increases CTLA4 PD1 Although CTLA4 checkpoint molecule Hardy Chaudhri 1997 Thompson Allison 1997 Walunas et al 1994 counterintuitively known induced early T cell activation Chambers et al 1996 In similar way PD1 highly expressed exhausted T cells marker T cell stimulation Jin et al 2011 Kansy et al 2017 Ngiow et al 2015 Thus increased CTLA4 PD1 associated pulsatile MEKi treatment suggests CD8 T cells activated supported data Ki67 expression Moreover considering exhausted T cells coexpress coinhibitory markers like TIM3 LAG3 simultaneously PD1 absence coinhibitory markers T cells pulsatile MEKi treatment supports activated exhausted cells Favorable changes CTLA4 pulsatile MEKi treatment warrant considering CTLA4 expression regulated It known CTLA4 regulated ERK Tsatsanis et al 2008 understood CTLA4 expression regulated temporally presence MEKis A future study mechanism CTLA4 expression regulation MEKis necessary Improved antitumor activity favorable phenotype CD8 T cells increased CTLA4 expression pulsatile group inspired test combination pulsatile MEKi treatment antiCTLA4 antibody Kras mutant lung cancer We combination pulsatile high doses selumetinib CTLA4 blockade prolonged survival greatest extent compared monotherapies combination therapies supporting combination immune checkpoint blockade pulsatile MEKis effective approach treat Kras lung cancer This prolonged survival present immunedeficient mice indicating mediated adaptive immune A similar pulsatile treatment regimen currently evaluation clinic NSCLC patients intermittent selumetinib antibodies targeting CTLA4 PDL1 ClinicalTrialgov NCT03581487 It noted trial Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 11 stratify comutations addition KRAS MEKi targets downstream KRAS restrain tumors KRAS mutation comutations combined immunotherapy In study tested MEK inhibition selumetinib trametinib However MEKis variations potency target specificity T¬Ω elimination halflife cobimetinib binimetinib development Caunt et al 2015 Based findings tested different dosing scheduling regimens potentially allow effective cancer cell growth control durable immune microenvironment activation In study pulsatile schedule alters tumor microenvironment favorably activating T cells providing advantageous antitumor effect Kras driven lung cancer models This schedule provides therapeutic window immune checkpoint blockade improve MEKis treatment KRASdriven NSCLC patients STARMETHODS CONTACT FOR REAGENT AND RESOURCE SHARING Further information requests resources reagents directed fulfilled Lead Contact Taha Merghoub merghoutmskccorg EXPERIMENTAL MODEL AND SUBJECT DETAILS Cell lines transplantable mouse modelCL13 CL25 IO33 cells lines Jones Bolin et al 1998 obtained Dr Phillip A Dennis Lastwika et al 2016 They cultured RPMI 75 FBS PenStrep The HKP1 cell line obtained Dr Vivek Mittal Weill Cornell Medical College Choi et al 2015 LLC Lewis Lung Carcinoma obtained ATCC CRL1642 HKP1 LLC cultured DMEM 10 fetal calf serum LGlutamine sodium pyruvate PenStrep Sex CL13 CL25 IO33 HKP1 LLC female based sequencing analysis KrasG12D p53ff cell line derived male mouse Dr KwokKin Wongs laboratory cultured RPMI 75 FBS PenStrep The cell lines kept culture limited number passage Cell lines routinely mycoplasma tested new cell line mycoplasma tested monoclonal core facility MSK Cell lines tested Mouse antibody production MAP routinely MSK All animal studies reviewed approved Institutional Animal Care Use Committee IACUC Memorial Sloan Kettering Cancer Center DanaFarber Cancer Institute All mice transplantable model 6 12 week old age females tumorbearing mice randomized selumetinib treatment 5 mice group flow cytometry analysis 10 mice group survival analysisTransplantable lung cancer generated intravenous injection 1 3 105 HKP1 cells C57BL6J Jax 00664 mice monitored IVIS Spectrum vivo imaging Perkin Elmer 50ul 30 mgml Dluciferine Perkin Elmer injected retroorbitally anesthesia isoflurane mice placed supine imaging chamber imaging Another transplantable model generated subcutaneous injection Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 12 500000 1000000 LLC cells flank C57BL6J Jax 00664 mice Rag1 Jax 002216 tumor growth measured calipers Mice treated selumetinib Selleckchem Houston TX USA day 5 day 7 examine effect MEKis tumor growth survival Selumetinib prepared corn oil administered oral gavage twice day 25mgkg continuous group daily 25mgkg 300mgkg cyclical pulsatile group according planned pulsatile schedule Survival analyzed based approved humane endpoints distress tumor size limit 100 ug antiCTLA4 administered mouse twice week 23 weeks intraperitoneally 9H10 clone doses 9D9 clone rest doses 250 ug antiPD1 RMP114 administered mouse twice week weeks intraperitoneally To deplete NK cells 200 ug antiNK11 antibody PK136 injected twice week weeks intraperitoneally GEMM model studiesAll animal studies reviewed approved Institutional Animal Care Use Committee IACUC DanaFarber Cancer Institute New York University School Medicine NYUSoM The genetically engineered mouse model GEMM harbors conditional activating mutation human version KRAS KRASLSLG12C collagen I locus Li et al 2018 CRE recombinase induced intranasal inhalation 25106 pfu adenoCre University Iowa adenoviral core Lung adenocarcinoma appeared 6 weeks induction For drug treatment studies GEMM models age matched littermates 15 21weekold induced time tumor burden monitored MRI Once tumor size reached 500 mm3 12 weeks adenoviral inoculation mice randomly assigned experimental groups We observe gender bias response male female mice terms tumor growth response drug treatment Mice evaluated MRI imaging quantify lung tumor burden drug treatment Mice treated vehicle 25 mgkg selumetinib twice daily oral gavage continuous day 3 weeks cyclical pulsatile week week dosing schedule PFS analyzed based standard criteria clinical trials Briefly PFS duration treatment start progression defined increase tumor size compared previous scan radiological CT appearance new lesions METHOD DETAILS In vitro MEKis treatmentSelumetinib trametnib Sellekchem added tumor cells 96well plates Viability measured CellTiter Glo luminescent viability kit Promega 72 hr Wallace plate reader Molecular Probe To determine pERK MEKis treatment Kras mutant lung tumor cell lines splenocytes collected HKP1 tumor bearing mice treated selumetinib trametinib 2 hr 37C Selumetinib trametinib stock solutions prepared DMSO diluted media Cells stimulated 01 ugml PMA 2 min 37C immediately fixed 4 paraformaldehyde permeabilized ice cold 95 methanol pERK stained antipERK 9106 Cell signaling goat antimouse IgHLFITC SouthernBiotech flow cytometry Washout experiments CD5 splenocytes HKP1 tumor bearing mice CD5 cells collected Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 13 CD5 microbeads Miltenyi MACS cell separation seeded presence selumetinib trametinib flat 96well plates precoated antiCD3 145 2C11 1ugml antiCD28 37N 1ugml After 24hrs media RIPA 75 FBS 01 bmercaptoethanol replaced MEKis continuous group DMSO diluent wash group media changed day freshly prepared MEKis At 72hrs 96 hr cells collected analyzed flow cytometry Western blotTrametinib vitro indicated doses 1 DMSO Cells treated 24 hours isolating protein Protein lysate isolated cultured cells RIPA buffer protease inhibitor 50mM Tris pH 8 150 mM NaCl 05 sodium deoxycholate 1 NP40 Protein quantification performed DC Lowry assay Antibodies pERK 4370 ERK¬Ω 9102 obtained Cell Signaling Technologies Ex vivo T cell priming MEKis treatmentPmel1 TCR transgenic mice Overwijk et al 2003 obtained Dr N Restifo National Institutes Health Splenocytes Pmel1 mouse stained 5uM CFSE Invitrogen seeded approximately 400000 cells Ushape 96 plate 1ugml heteroclitic human gp100 peptide AnaSpec Inc day 0 01 bmercaptoenthanol supplemented RPMI media 75 FBS At time splenocytes Pmel1 mouse set priming T175 flask At day 2 3 20U mouse IL2 eBioscience added supernatant T175 flask subsequently prepare following treatment groups plate Supernatant MEKis selumetinib trametinib added continuous groups according experimental plan Washout groups treated supernatant containing IL2 DMSO At day 4 5 20Uml mouse IL2 supplemented fresh T cell media MEKis added support extensive cell growth cells stained analyzed day 5 flow cytometry MRI quantificationAnimals anesthetized isoflurane perform magnetic resonance imaging MRI lung field BioSpec USR70 30 horizontal bore Bruker scan 24 consecutive sections Overall tumor volumes lung quantified 3D slicer software reconstruct MRI volumetric measurements previously described Chen et al 2012 Acquisition MRI signal adapted according cardiac respiratory cycles minimize motion effects imaging Tumorinfiltrating immune cells isolation analysisMice sacrificed lungs perfused sterile PBS heart perfusion right ventricle The lung minced small pieces digested collagenase D Sigma GIBCO DNase I Sigma Hanks Balanced Salt Solution HBSS 37 C 30 min After incubation digested tissue filtered 40 um 70 mm cell strainer Fisher obtain singlecell suspensions Separated cells treated 1X RBC lysis buffer Biolegend lyse red blood cells Live cells determined LIVEDEAD fixable aqua dead cell stain kit Molecular Probes Fixable viability dye e506 eBioscience The cell pellets resuspended PBS 2 FBS flow cytometry analysis Cells stained cell surface markers indicated followed fixationpermeabilization Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 14 foxp3 fixationpermeabilization kit eBioscience Lung infiltrating immune cells stained different combinations fluorochromecoupled antibodies analyzed FACS analysis Transcriptome analysisRNA extracted 6 10 FFPE tissue sections QUICK RNA FFPE kit Zymo Research Expression profiling performed Affymetrix Clariom D Pico Assay mouse analyzed Transcriptome Analysis Console previously described Andrzejewski et al 2017 Nassal et al 2017 Heatmaps plotted R Robust Multiarray Average RMA procedure Bolstad et al 2003 Carvalho Irizarry 2010 Irizarry et al 2003a Irizarry et al 2003b Expression values normalized Affymetrix mta10 annotation data gene names translated MGI symbols Heatmaps signature gene sets extracted study Brant et al Brant et al 2017 Flow cytometry analysisImmune cells obtained ex vivo treatment vivo collected processed singlecell suspensions stained antibodies mouse CD3 1452C11 CD62L MEL14 CD44 IM7 Tbet eBio4B10 CD45 30F11 PD1 J43 41BB 17B5 CTLA4 UC104B9 Ki67 SolA15 Foxp3 FJK16 s CD4 GK15 CD8 3B5 fixable viability dye 506 eBioscience ex vivo studies antibodies mouse CD3 17A2 CD4 GK15 CD8 5367 5H19 Foxp3 FJK16 s CD11b M170 CD11c N418 Epcam G88 CD279 PD1 29F1A12 J43 CD152 CTLA4 UC104B9 TIM3 RMT323 CD223 Lag3 C9B7W ICOS c3984A 41BB 17B5 GITR DTA1 OX40 OX86 PDL1 10F9G2 vivo studies Staining signals acquired BD LSRFortessa BD LSR II BD Biosciences analyzed FlowJo software FlowJo LLC Cytokine profiling analysisThe supernatant primed Pmel1 selumetinib collected day 5 human gp100 peptide addition subjected Luminex cytokine analysis Luminex MAGPIX Milliplex multiplex assays mouse panel Millipore analyzed xPOTENT software Millipore Sigma Mouse lung bronchoalveolar lavage BAL GEMM KRASG1C mice treatment performed intratracheal injection 2ml sterile PBS collected aspiration Cytokines measured Mouse Cytokine 23plex Assay BioRad measured BioPlex 200 BioRad Concentrations pgml protein derived 5parameter curve fitting models Fold changes relative control calculated plotted log2FC Lower upper limits quantitation LLOQULOQ derived standard curves cytokines detection Immunohistochemistry IHC staining analysesParaffinembedded sections deparaffinized followed immunohistochemical staining antibodies pERK Cell Signaling examined Leica upright microscope Liu et al 2015b HE sections examined pathologist DanaFaber Cancer Institute Results independently scored pathologists multiplicative quick systems Liu et al 2015b Briefly expression score marker calculated multiplying score indicating percentage positively stained cells tumor cells counted 1 04 2 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 15 519 3 2039 4 4059 5 6079 6 80100 intensity grade staining 0 negative 1 weak 2 moderate 3 strong QUANTIFICATION AND STATISTICAL ANALYSIS Statistical AnalysisData presented mean SEM specified Statistical comparisons performed unpaired Students t tests tailed p value specified p 005 p 001 p 0001 Survival analyzed Logrank analysis Graphad Prism 7 DATA AND SOFTWARE AVAILABILITY Data ResourcesThe accession number Affymetrix transcriptome analysis reported paper GEO GSE126202 Supplementary Material Refer Web version PubMed Central supplementary material ACKNOWLEDGMENTS We thank Nouraiz Falik work validation animal experiments This research funded Stand Up To CancerAmerican Cancer Society Lung Cancer Dream Team Translational Research Grant SU2C AACRDT1715 NIHNCI Cancer Center Support grant P30 CA008748 Ludwig Collaborative Swim Across America Laboratory Memorial Sloan Kettering Cancer Center United States Parker Institute Cancer Immunotherapy Memorial Sloan Kettering Cancer Center Department Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medicine United States REFERENCES Andrzejewski S Klimcakova E Johnson RM Tabari√©s S Annis MG McGuirk S Northey JJ Ch√©nard V Sriram U Papadopoli DJ et al 2017 PGC1a promotes breast cancer metastasis confers bioenergetic flexibility metabolic drugs Cell Metab 26 778787e5 PubMed 28988825 Bolstad BM Irizarry RA Astrand M Speed TP 2003 A comparison normalization methods high density oligonucleotide array data based variance bias Bioinformatics 19 185193 PubMed 12538238 Borghaei H PazAres L Horn L Spigel DR Steins M Ready NE Chow LQ Vokes EE Felip E Holgado E et al 2015 Nivolumab versus docetaxel advanced nonsquamous nonsmallcell lung cancer N Engl J Med 373 16271639 PubMed 26412456 Brahmer J Reckamp KL Baas P Crin√≤ L Eberhardt WEE Poddubskaya E Antonia S Pluzanski A Vokes EE Holgado E et al 2015 Nivolumab versus docetaxel advanced squamouscell nonsmallcell lung cancer N Engl J Med 373 123135 PubMed 26028407 Brant R Sharpe A Liptrot T Dry JR Harrington EA Barrett JC Whalley N Womack C Smith P Hodgson DR 2017 Clinically viable gene expression assays potential predicting benefit MEK inhibitors Clin Cancer Res 23 14711480 PubMed 27733477 Brea EJ Oh CY Manchado E Budhu S Gejman RS Mo G Mondello P Han JE Jarvis CA Ulmert D et al 2016 Kinase regulation human MHC class I molecule expression cancer cells Cancer Immunol Res 4 936947 PubMed 27680026 Callahan MK Masters G Pratilas CA Ariyan C Katz J Kitano S Russell V Gordon RA Vyas S Yuan J et al 2014 Paradoxical activation T cells augmented ERK signaling mediated RAF inhibitor Cancer Immunol Res 2 7079 Carvalho BS Irizarry RA 2010 A framework oligonucleotide microarray preprocessing Bioinformatics 26 23632367 PubMed 20688976 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 16 Caunt CJ Sale MJ Smith PD Cook SJ 2015 MEK1 MEK2 inhibitors cancer therapy long winding road Nat Rev Cancer 15 577592 PubMed 26399658 Chambers CA Krummel MF Boitel B Hurwitz A Sullivan TJ Fournier S Cassell D Brunner M Allison JP 1996 The role CTLA4 regulation initiation Tcell responses Immunol Rev 153 2746 PubMed 9010718 Chen Z Cheng K Walton Z Wang Y Ebi H Shimamura T Liu Y Tupper T Ouyang J Li J et al 2012 A murine lung cancer coclinical trial identifies genetic modifiers therapeutic response Nature 483 613617 PubMed 22425996 Choi H Sheng J Gao D Li F Durrans A Ryu S Lee SB Narula N Rafii S Elemento O et al 2015 Transcriptome analysis individual stromal cell populations identifies stromatumor crosstalk mouse lung cancer model Cell Rep 10 11871201 PubMed 25704820 DSouza WN Chang CF Fischer AM Li M Hedrick SM 2008 The Erk2 MAPK regulates CD8 T cell proliferation survival J Immunol 181 76177629 PubMed 19017950 Das Thakur M Salangsang F Landman AS Sellers WR Pryer NK Levesque MP Dummer R McMahon M Stuart DD 2013 Modelling vemurafenib resistance melanoma reveals strategy forestall drug resistance Nature 494 251255 PubMed 23302800 Dushyanthen S Teo ZL Caramia F Savas P Mintoff CP Virassamy B Henderson MA Luen SJ Mansour M Kershaw MH et al 2017 Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy breast cancer Nat Commun 8 606 PubMed 28928458 Ebert PJR Cheung J Yang Y McNamara E Hong R Moskalenko M Gould SE Maecker H Irving BA Kim JM et al 2016 MAP kinase inhibition promotes T cell antitumor activity combination PDL1 checkpoint blockade Immunity 44 609621 PubMed 26944201 Fern√°ndezMedarde A Santos E 2011 Ras cancer developmental diseases Genes Cancer 2 344358 PubMed 21779504 Friday BB Adjei AA 2008 Advances targeting RasRafMEK Erk mitogenactivated protein kinase cascade MEK inhibitors cancer therapy Clin Cancer Res 14 342346 PubMed 18223206 Garon EB Rizvi NA Hui R Leighl N Balmanoukian AS Eder JP Patnaik A Aggarwal C Gubens M Horn L et al KEYNOTE001 Investigators 2015 Pembrolizumab treatment nonsmallcell lung cancer N Engl J Med 372 20182028 PubMed 25891174 Greystoke A Steele N Arkenau HT Blackhall F Md Haris N Lindsay CR Califano R Voskoboynik M Summers Y So K et al 2017 SELECT3 phase I study selumetinib combination platinumdoublet chemotherapy advanced NSCLC firstline setting Br J Cancer 117 938946 PubMed 28950288 Hardy K Chaudhri G 1997 Activation signal transduction mitogenactivated protein MAP kinases T lymphocytes Immunol Cell Biol 75 528545 PubMed 9492189 Hellmann MD Rizvi NA Goldman JW Gettinger SN Borghaei H Brahmer JR Ready NE Gerber DE Chow LQ Juergens RA et al 2017 Nivolumab plus ipilimumab firstline treatment advanced nonsmallcell lung cancer CheckMate 012 results openlabel phase 1 multicohort study Lancet Oncol 18 3141 PubMed 27932067 Holmstr√∂m TH Schmitz I S√∂derstr√∂m TS Poukkula M Johnson VL Chow SC Krammer PH Eriksson JE 2000 MAPKERK signaling activated T cells inhibits CD95Fasmediated apoptosis downstream DISC assembly EMBO J 19 54185428 PubMed 11032809 Irizarry RA Bolstad BM Collin F Cope LM Hobbs B Speed TP 2003a Summaries Affymetrix GeneChip probe level data Nucleic Acids Res 31 e15 PubMed 12582260 Irizarry RA Hobbs B Collin F BeazerBarclay YD Antonellis KJ Scherf U Speed TP 2003b Exploration normalization summaries high density oligonucleotide array probe level data Biostatistics 4 249264 PubMed 12925520 JamalHanjani M Wilson GA McGranahan N Birkbak NJ Watkins TBK Veeriah S Shafi S Johnson DH Mitter R Rosenthal R et al TRACERx Consortium 2017 Tracking evolution nonsmallcell lung cancer N Engl J Med 376 21092121 PubMed 28445112 Jin HT Ahmed R Okazaki T 2011 Role PD1 regulating Tcell immunity Curr Top Microbiol Immunol 350 1737 PubMed 21061197 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 17 JonesBolin SE Johansson E Palmisano WA Anderson MW Wiest JS Belinsky SA 1998 Effect promoter intron 2 polymorphisms murine lung Kras gene expression Carcinogenesis 19 15031508 PubMed 9744549 Kane LP Lin J Weiss A 2000 Signal transduction TCR antigen Curr Opin Immunol 12 242249 PubMed 10781399 Kansy BA ConchaBenavente F Srivastava RM Jie HB Shayan G Lei Y Moskovitz J Moy J Li J Brandau S et al 2017 PD1 status CD8 T cells associates survival antiPD1 therapeutic outcomes head neck cancer Cancer Res 77 63536364 PubMed 28904066 Lastwika KJ Wilson W 3rd Li QK Norris J Xu H Ghazarian SR Kitagawa H Kawabata S Taube JM Yao S et al 2016 Control PDL1 expression oncogenic activation AKTmTOR pathway nonsmall cell lung cancer Cancer Res 76 227238 PubMed 26637667 Li S Liu S Deng J Akbay EA Hai J Ambrogio C Zhang L Zhou F Jenkins RW Adeegbe DO et al 2018 Assessing therapeutic efficacy MEK inhibition KRASSUPG12CSUPdriven mouse model lung cancer Clin cancer res 24 48544864 PubMed 29945997 Liu L Mayes PA Eastman S Shi H Yadavilli S Zhang T Yang J SeestallerWehr L Zhang SY Hopson C et al 2015a The BRAF MEK inhibitors dabrafenib trametinib effects immune function combination immunomodulatory antibodies targeting PD1 PDL1 CTLA4 Clin Cancer Res 21 16391651 PubMed 25589619 Liu X Yu X Xie J Zhan M Yu Z Xie L Zeng H Zhang F Chen G Yi X Zheng J 2015b ANGPTL2LILRB2 signaling promotes propagation lung cancer cells Oncotarget 6 2100421015 PubMed 26056041 Lovly CM Carbone DP 2011 Lung cancer 2010 size fit Nat Rev Clin Oncol 8 6870 PubMed 21278771 Manchado E Weissmueller S Morris JP 4th Chen CC Wullenkord R Lujambio A Stanchina E Poirier JT Gainor JF Corcoran RB et al 2016 A combinatorial strategy treating KRAS mutant lung cancer Nature 534 647651 PubMed 27338794 Nassal DM Wan X Liu H Maleski D RamirezNavarro A Moravec CS Ficker E Laurita KR Desch√™nes I 2017 KChIP2 core transcriptional regulator cardiac excitability eLife 6 e17304 PubMed 28263709 Ngiow SF Young A Jacquelot N Yamazaki T Enot D Zitvogel L Smyth MJ 2015 A threshold level intratumor CD8 Tcell PD1 expression dictates therapeutic response antiPD1 Cancer Res 75 38003811 PubMed 26208901 Ostrem JM Peters U Sos ML Wells JA Shokat KM 2013 KRasG12C inhibitors allosterically control GTP affinity effector interactions Nature 503 548551 PubMed 24256730 Overwijk WW Theoret MR Finkelstein SE Surman DR Jong LA VythDreese FA Dellemijn TA Antony PA Spiess PJ Palmer DC et al 2003 Tumor regression autoimmunity reversal functionally tolerant state selfreactive CD8 T cells J Exp Med 198 569580 PubMed 12925674 Planchard D Smit EF Groen HJM Mazieres J Besse B Helland √Ö Giannone V DAmelio AM Jr Zhang P Mookerjee B Johnson BE 2017 Dabrafenib plus trametinib patients previously untreated BRAFV600Emutant metastatic nonsmallcell lung cancer openlabel phase 2 trial Lancet Oncol 18 13071316 PubMed 28919011 Poon E Mullins S Watkins A Williams GS Koopmann JO Di Genova G Cumberbatch M Veldman Jones M Grosskurth SE Sah V et al 2017 The MEK inhibitor selumetinib complements CTLA4 blockade reprogramming tumor immune microenvironment J Immunother Cancer 5 63 PubMed 28807001 Reck M Rodr√≠guezAbreu D Robinson AG Hui R Cs≈ëszi T F√ºl√∂p A Gottfried M Peled N Tafreshi A Cuffe S et al KEYNOTE024 Investigators 2016 Pembrolizumab versus chemotherapy PDL1positive nonsmallcell lung cancer N Engl J Med 375 18231833 PubMed 27718847 Riely GJ Marks J Pao W 2009 KRAS mutations nonsmall cell lung cancer Proc Am Thorac Soc 6 201205 PubMed 19349489 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 18 Rinc√≥n M Flavell RA Davis RJ 2001 Signal transduction MAP kinases T lymphocytes Oncogene 20 24902497 PubMed 11402343 Samatar AA Poulikakos PI 2014 Targeting RASERK signalling cancer promises challenges Nat Rev Drug Discov 13 928942 PubMed 25435214 Shah NP Kasap C Weier C Balbas M Nicoll JM Bleickardt E Nicaise C Sawyers CL 2008 Transient potent BCRABL inhibition sufficient commit chronic myeloid leukemia cells irreversibly apoptosis Cancer Cell 14 485493 PubMed 19061839 Solit DB She Y Lobo J Kris MG Scher HI Rosen N Sirotnak FM 2005 Pulsatile administration epidermal growth factor receptor inhibitor gefitinib significantly effective continuous dosing sensitizing tumors paclitaxel Clin Cancer Res 11 1983 1989 PubMed 15756024 Soria JC F√ºlop A Maciel C Fischer JR Girotto G Lago S Smit E Ostoros G Eberhardt WEE Lishkovska P et al 2017 SELECT2 phase II doubleblind randomised placebocontrolled study assess efficacy selumetinib plus docetaxel secondline treatment patients advanced metastatic nonsmall cell lung cancer Ann Oncol 28 30283036 PubMed 29045535 Stinchcombe TE Johnson GL 2014 MEK inhibition nonsmall cell lung cancer Lung Cancer 86 121125 PubMed 25257766 Sun C Hobor S Bertotti A Zecchin D Huang S Galimi F Cottino F Prahallad A Grernrum W Tzani A et al 2014 Intrinsic resistance MEK inhibition KRAS mutant lung colon cancer transcriptional induction ERBB3 Cell Rep 7 8693 PubMed 24685132 Swanton C Govindan R 2016 Clinical implications genomic discoveries lung cancer N Engl J Med 374 18641873 PubMed 27168435 Thompson CB Allison JP 1997 The emerging role CTLA4 immune attenuator Immunity 7 445450 PubMed 9354465 Tsatsanis C Vaporidi K Zacharioudaki V Androulidaki A Sykulev Y Margioris AN Tsichlis PN 2008 Tpl2 ERK transduce antiproliferative T cell receptor signals inhibit transformation chronically stimulated T cells Proc Natl Acad Sci USA 105 29872992 PubMed 18287049 Walunas TL Lenschow DJ Bakker CY Linsley PS Freeman GJ Green JM Thompson CB Bluestone JA 1994 CTLA4 function negative regulator T cell activation Immunity 1 405413 PubMed 7882171 Weiss A Littman DR 1994 Signal transduction lymphocyte antigen receptors Cell 76 263 274 PubMed 8293463 Wolchok JD Kluger H Callahan MK Postow MA Rizvi NA Lesokhin AM Segal NH Ariyan CE Gordon RA Reed K et al 2013 Nivolumab plus ipilimumab advanced melanoma N Engl J Med 369 122133 PubMed 23724867 Zeng M Lu J Li L Feru F Quan C Gero TW Ficarro SB Xiong Y Ambrogio C Paranal RM et al 2017 Potent selective covalent quinazoline inhibitors KRAS G12C Cell Chem Biol 24 10051016e3 PubMed 28781124 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 19 Highlights Pulsatile treatment MEK inhibitors maintains T cell activation Pulsatile dosing MEK inhibitor delays growth rebound KRAS mutant lung tumors Combining CTLA4 blockade pulsatile MEK inhibition extends survival The enhanced survival conferred adaptive immunity Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 20 Figure 1 MEK Inhibition Affects Murine Kras Mutant Tumor Growth Murine T Cell Signaling A pERK expression Kras mutant lung cancer cell lines trametinib treatment western blot B Viability lung tumor cell lines selumetinib treatment Samples biological replicates C Survival HKP1 lungcancerbearing mice 3 weeks selumetinib treatment D pERK expression CD4 CD8 T cells HKP1 tumorbearing lungs selumetinib trametinib treatment flow cytometry Samples biological replicates p 005 p 001 p 0001 p 00001 Welchs t test NS significant Error bars represent SD The experiments performed 23 times representative results shown Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 21 Figure 2 Short Schedule MEKi Treatment Alters T Cell Activation Status Ex Vivo A Schema ex vivo short versus long treatment experiment B CTLA4 PD1 Ki67 41BB expression CD8 T cells CD4Foxp3 cells flow cytometry selumetinib left trametinib right treatment 96 hr p 005 p 001 Welchs test Error bars represent SD Samples biological replicates The experiment performed twice representative results shown Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 22 Figure 3 Short Treatment MEKis Alters T Cell Priming Ex Vivo A Schema short treatment Pmel1 CD8 T cells human gp100 peptide pulse B Flow cytometry plots CD44 CD62L markers CD8 T cells 5 days priming C Frequency CD44 CD62L subsets CD8 T cells flow cytometry analysis Average percentage subset presented D Frequency CD44 CD62L cell population flow cytometry E IFNŒ≥ production supernatant day 5 cytokine profiling p 005 p 001 p 0001 Welchs test Error bars represent SD Samples biological replicates The experiment performed twice representative results shown Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 23 Figure 4 Pulsatile Treatment Selumetinib Induces CTLA4 PD1 Expression In Vivo HKP1 transplantable lungtumorbearing mice treated selumetinib 25 mgkg BID presented A After 2 weeks treatment lungs collected analyzed flow cytometry A Schema selumetinib treatment HKP1 lungtumorbearing mice vivo B Frequency CD3 T cell subsets lung tumors flow cytometry C Ki67 diverse cell populations lung tumors flow cytometry D Scatterplots PD1 CTLA4 marker left coinhibitory marker expression CD3 T cell subsets lung tumors flow cytometry right Gating controls samples PD1 CTLA4 antibodies p 005 p 001 p 0001 MannWhitney test Samples biological replicates The experiment performed 3 times representative results shown Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 24 Figure 5 Pulsatile Schedule MEKi Treatment Delays Tumor Growth In Vivo A Schema selumetinib treatment KRASG12C mutant genetically engineered mouse model GEMM lung cancer Treatment schedule continuous treatment upper panel 25 mgkg BID pulsatile treatment lower panel 25 mgkg BID B Waterfall plot showing tumor volume change indicated time points continuous treatment selumetinib C Waterfall plot showing tumor volume change indicated time points treatment pulsatile dosing vehicle left panel selumetinib right panel D Representative images immunohistochemistry IHC staining pERK left panels multiplicative quick scores quantification pERK¬Ω staining vehicle control pulsatile selumetinib continuous selumetinib tumor tissue samples end treatment right panel Scale bars 100 mm p 005 p 00001 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 25 E Progressionfree survival KRASG12C mice treated vehicle control pulsatile selumetinib continuous selumetinib p 001 p 0001 Samples biological replicates This treatment study performed times results mice combined presented Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 26 Figure 6 Coinhibitory Signaling Was Altered Differentially Continuous versus Pulsatile Treatment MEKis A Flow cytometry analysis KRASG12C mutant GEMM lungtumorinfiltrating T cell subpopulations CD4 CD8 Tregs CD4Foxp3 continuous left pulsatile right treatment selumetinib presented Figure 5A Lung tumors collected end treatment p 005 NS significant B Representative flow cytometry analysis PD1 levels CD4 CD8 tumor infiltrating T cells continuous treatment selumetinib C Quantification inhibitory immune checkpoint molecule expression CD4 upper CD8 lower T cells 3 weeks continuous selumetinib treatment p 005 p 001 D Quantification inhibitory molecules CD4 left CD8 right T lymphocyte subpopulations 3 cycles pulsatile selumetinib treatment p 001 Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 27 Samples biological replicates All mice recruited time treatment results mice shown Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 28 Figure 7 Pulsatile Treatment Selumetinib High Dosage Impacts Immune Microenvironment Differently Enhances Survival Combination AntiCTLA4 Treatment A Schema dosing sample collection highdose Hi 600 mgkg day left panel lowdose Lo 50 mgkgday right panel selumetinib treatment KrasG12DTrp53flfl murine transplantable tumors treated different dosages selumetinib Mouse lung tumors collected indicated time points Samples biological replicates B Flow cytometry analysis different tumorinfiltrating T cell subpopulations total infiltrating CD45 leukocytes indicated time points left PDL1 expression levels tumor cells EpCAM myeloid cells CD11b T cells CD4 CD8 middle Ki67 expression right C Quantification inhibitory immune checkpoint molecules expressed CD4 left CD8 right T cells Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 29 D Schema selumetinib antiCTLA4 treatment LLC transplantable tumor model E Survival curve selumetinib antiCTLA4 treatment combination immunecompetent mice C57BL6J F Survival curve selumetinib antiCTLA4 treatment combination immunedeficient mice Rag1 The color code F G Survival pulsatile selumetinib antiCTLA4 treatment group Survival analysis Logrank MantelCox test 005 001 Samples biological replicates The experiment performed 23 times representative results shown Cell Rep Author manuscript available PMC 2019 September 03 Choi et al Page 30 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t R E I F I T N E D I E C R U O S 2 8 0 4 9 3 _ B A D R R I 8 5 5 2 6 5 0 1 _ B A D R R I 3 6 1 1 5 5 8 0 1 1 6 5 t C n e g n M r h P D B 7 7 4 6 3 2 1 _ B A D R R I 6 9 6 2 1 3 _ B A D R R I 1 9 6 2 1 3 _ B A D R R I 3 7 9 2 1 3 _ B A D R R I 8 3 2 5 7 0 2 _ B A D R R I 5 1 2 8 1 1 t C 1 1 4 0 0 1 t C 6 0 4 0 0 1 t C 8 0 1 3 0 1 t C 4 3 7 0 0 1 t C 9 8 5 4 7 3 0 1 _ B A D R R I 7 1 8 0 D C M t C 6 5 4 9 6 4 _ B A D R R I 0 8 3 7 7 5 7 1 t C 2 5 5 1 9 8 _ B A D O R R 2 8 3 7 7 5 5 2 t C 1 9 5 5 9 5 1 _ B A D R R I 3 6 6 2 6 5 2 _ B A D R R I 5 2 8 5 0 5 t C 1 1 4 2 5 6 t C 4 2 1 9 4 1 1 1 _ B A D R R I 2 8 8 9 6 5 8 4 t C 1 5 0 0 7 4 _ B A D R R I 1 8 1 2 3 4 2 1 t C 1 2 5 6 2 3 _ B A D R R I 7 1 5 6 2 3 _ B A D R R I 5 1 4 0 0 4 t C 1 1 4 0 0 4 t C d n e g e L o B d n e g e L o B d n e g e L o B d n e g e L o B s d n e g e L o B n e g o r t v n I e c n e c s o B e e c n e c s o B e d n e g e L o B d n e g e L o B n e g o r t v n I d n e g e L o B d n e g e L o B e c n e c s o B e 3 7 4 5 6 4 _ B A D R R I 5 8 5 8 9 9 1 1 t C 2 2 4 6 9 6 0 1 _ B A D R R I 5 1 2 5 3 1 t C 8 7 8 5 6 4 _ B A D R R I 0 0 7 6 1 0 2 _ B A D R R I 1 8 2 2 5 1 2 1 t C 2 8 2 2 5 1 7 1 t C 5 3 9 9 3 6 0 1 _ B A D R R I 9 0 2 5 2 1 t C 6 6 8 9 4 1 1 1 _ B A D R R I 2 8 1 3 2 2 8 4 t C 3 7 0 0 7 4 _ B A D R R I 1 8 8 8 8 4 2 1 t C 5 3 9 2 1 6 0 1 _ B A D R R I 1 1 3 4 2 1 t C 5 4 6 3 9 4 _ B A D R R I 4 7 3 7 5 0 2 _ B A D R R I 4 1 2 0 0 1 t C 1 2 2 0 0 1 t C 5 2 5 4 6 4 1 _ B A D R R I 7 1 8 2 M R t C 9 4 6 0 3 8 _ B A D R R I 4 2 3 7 1 1 t C 6 8 9 5 5 7 _ B A D R R I 4 2 2 1 0 1 t C d n e g e L o B n e g o r t v n I d n e g e L o B e c n e c s o B e d n e g e l o B r e h s F o m r e h T e c n e c s o B e d n e g e L o B e c n e c s o B e d n e g e L o B r e h s F o m r e h T d n e g e L o B s d n e g e L o B 2 7 7 1 3 3 _ B A D R R I 8 6 7 1 3 3 _ B A D R R I 2 1 1 5 1 3 2 _ B A D R R I 4 4 7 0 3 3 _ B A D R R I 6 7 3 4 t C 6 0 1 9 t C 0 7 3 4 t C 2 0 1 9 t C y g o l o n h c e T g n l n g S l l e C y g o l o n h c e T g n l n g S l l e C y g o l o n h c e T g n l n g S l l e C y g o l o n h c e T g n l n g S l l e C E L B A T S E C R U O S E R Y E K E 4 4 1 3 1 D 2 1 k r E K P A M 2 4 4 4 p o h p s o h p 1 1 G 0 2 2 1 k r E K P A M 2 4 4 4 p o h p s o h p 0 1 E 2 1 k r E K P A M 2 4 4 4 p o h p s o h p E C R U O S E R r o T N E G A E R s e d o b t n A 2 1 k r E K P A M 2 4 4 4 P 5 1 0 7 1 M b 1 1 D C 0 7 1 M b 1 1 D C 8 1 4 N c 1 1 D C 3 4 J 1 D P 2 1 A 1 F 9 2 1 D P 9 B 4 0 1 C U 4 A L T C 9 B 4 0 1 C U 4 A L T C W 7 B 9 C 3 G A L W 7 B 9 C o B e 3 G A L 2 G 9 F 0 1 1 L D P r m A 9 9 2 o B e G g I r e t s m H n n e m A r y r t e m o t y c w o l f r o f 2 A 7 1 3 D C y r t e m o t y c w o l f r o f 2 A 7 1 3 D C 1 1 C 2 5 4 1 3 D C 8 8 G M A C p E 5 1 K G 4 D C 5 1 K G 4 D C 1 1 F 0 3 5 4 D C 7 6 3 5 8 D C 9 1 H 5 8 D C s 6 1 K J F 3 P x o F s 6 1 K J F 3 P x o F 2 1 G M X Œ≥ N F I 5 1 A l o S 7 6 K 8 A 6 1 7 6 K 1 7 0 2 K T R 1 G g I 1 7 0 2 K T R 1 G g I 2 R B e 2 G g I Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Choi et al Page 31 1 8 1 0 7 4 _ B A D R R I 1 8 1 2 3 4 7 1 t C R E I F I T N E D I 7 2 4 3 3 9 0 1 _ B A D R R I 2 4 5 6 2 3 _ B A D R R I 1 2 5 0 0 4 t C 5 3 5 0 0 4 t C 3 7 9 5 6 4 _ B A D R R I 1 6 7 5 2 9 _ B A D R R I 8 5 4 5 6 4 _ B A D R R I 5 6 8 5 6 4 _ B A D R R I 4 9 3 4 4 9 1 _ B A D R R I 0 6 2 7 1 7 0 1 _ B A D R R I 3 0 0 4 9 4 _ B A D R R I 1 8 0 7 8 5 2 1 t C 2 8 5 2 8 5 2 1 t C 2 8 9 4 9 9 1 1 t C 3 8 1 7 3 1 2 1 t C 2 8 4 7 8 5 8 4 t C 2 8 1 4 3 1 7 1 t C 2 8 1 2 6 0 6 5 t C E C R U O S e c n e c s o B e d n e g e L o B d n e g e L o B e c n e c s o B e e c n e c s o B e e c n e c s o B e e c n e c s o B e e c n e c s o B e e c n e c s o B e e c n e c s o B e 1 6 6 8 9 3 _ B A D R R I 0 5 2 9 5 5 t C n e g n M r h P D B 2 G 4 2 e n o l C e r o C e c r u o s e r o B d n y d o b t n A K S M 4 8 1 0 5 9 0 1 _ B A D R R I 9 0 6 9 4 9 0 1 _ B A D R R I 2 8 7 7 0 1 1 _ B A D R R I 1 9 7 7 0 1 1 _ B A D R R I 3 5 0 9 4 9 0 1 _ B A D R R I 9 6 7 7 0 1 1 _ B A D R R I 1 3 1 0 E B t C 4 6 1 0 E B t C 7 8 0 0 E B t C 6 8 0 0 E B t C 6 4 1 0 E B t C 9 8 0 0 E B t C 7 3 7 7 0 1 1 _ B A I D R R 6 3 0 0 E B t C l l e c x o B l l e c x o B l l e c x o B l l e c x o B l l e c x o B l l e c x o B l l e c x o B 1 1 C 2 5 4 1 e n o l C e r o C e c r u o s e r o B d n y d o b t n A K S M N 7 3 e n o l C e r o C e c r u o s e r o B d n y d o b t n A K S M 5 w o I f o U C V V b e W e r o C r o t c e V l r V I U 4 6 1 2 0 8 4 1 t C 4 1 6 6 8 0 5 6 t C 9 8 5 2 6 S A t C 8 0 0 1 S t C 3 7 6 2 S t C 1 0 3 9 4 0 0 3 1 t C 6 6 9 4 3 L t C m e h c k c e l l e S m e h c k c e l l e S c n I c e p s n A e c n e c s o B e e c n e c s o B e r e h s F o m r e h T y n e t l M 1 1 P C M l o r t n o c e p y t o s b 2 G g I e s u o m b A M o v V n I t n e m r e p x e o viv r o f 4 1 1 P M R 1 D P t n e s u o m 3 A 2 l o r t n o c e p y t o s 2 G g I t r b A M o v V n I y d o b t n o viv 6 3 1 K P 1 1 K N y d o b t n o viv 0 1 H 9 4 A L T C t n e s u o m y d o b t n o viv 9 D 9 4 A L T C t n e s u o m G g I r e t s m H n r y S n o t v t c l l e c T o vitr r o f 3 D C n o t v t c l l e c T o vitr r o f 8 2 D C d e f r u p m m g c F t n A s n e t o r P t n n b m o c e R d n s e d t p e P s l c m e h C s n r t S s u r V d n l r e t c B e r C V M C 5 d A t K n t S l l e C d e D u q A e l b x F D A E D E V I L e s u o m s d e B o r c M 1 y L 5 D C y r t e m o t y c w o l f r o f e y d y t l b v e l b x F s y s s A l c r e m m o C l c t r C 2 L I e s u o m t n n b m o c e R n m u h e d t p e p 0 0 1 p g b n t e m u l e S b n t e m r T E C R U O S E R r o T N E G A E R 8 5 7 2 K T R 2 G g I 8 5 7 2 K T R 2 G g I 3 2 3 T M R 3 M I T 2 R B e 2 G g I 0 1 B 4 o B e t e b T A 4 8 9 3 c S O C I 5 B 7 1 B B 1 4 1 A T D R T I G 6 8 X O 0 4 X O 4 1 L E M L 2 6 D C 7 M I 4 4 D C Cell Rep Author manuscript available PMC 2019 September 03 A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t 2 3 X P K 0 7 G A M T Y C M t C e r o p l l M y s s A x e l p t l u M y g o l o n u m m I l e n P d e B c t e n g M e n k o m e h C e n k o t y C e s u o M P A M X E L P I L L I M e s u o m s s y l n e n k o t y c x e n m u L R E I F I T N E D I E C R U O S E C R U O S E R r o T N E G A E R Choi et al Page 32 I A A E 9 U A e L 0 h C I T 4 k V A 4 W K L _ N 2 K o I M h C b o Q I I A E d l c g E w B _ D _ r w L g E C A S A Y g n g m o v v n y r o g e t c m o c r e m l e n k r e p w w w p t t h e r w t f o s x r t e m y f f e r w t f o s s s y l n y r r o r c m s e c v r e s e r w t f o s e c n e c s e f l e m o h n e s u m o c r e h s f o m r e h t w w w s p t t h s t n e m u r t s n s s y l n y r r o r c m s s y l n y r r o r c m l m t h e r w t f o s e l o s n o c s s y l n e m o t p r c s n r t m s r p e r w t f o s c f t n e c s m o c d p h p r g w w w s p t t h s d o l n w o d o j w o l f s n o t u l o s m o c o j w o l f w w w s p t t h g r o r e c l s w w w s p t t h 4 7 6 5 2 9 2 1 I D M P 6 1 2 2 0 0 x J 4 6 6 0 0 0 x J H N I y r o t r o b l o f t s e R s l o h c N r D b l x J b l x J d o l n w o d e n l n O d o l n w o d e n l n O d o l n w o d e n l n O l r e m E n k r e P d p d r 9 0 0 0 6 m 1 7 5 7 G 8 0 0 1 R h c r e s e R o m y Z d R o B g e m o r P 2 0 2 6 2 1 E S G O E G s u b n m O n o s s e r p x E e n e G I B C N 7 6 6 7 3 6 6 2 I D M P 7 6 6 7 3 6 6 2 I D M P 7 6 6 7 3 6 6 2 I D M P s n n e D A p l l h P r D s n n e D A p l l h P r D s n n e D A p l l h P r D 2 4 6 1 L R C C C T A C C T A 0 2 8 4 0 7 5 2 I D M P C M C W y r o t r o b l l t t M k e v V r D A N U Y N y r o t r o b l g n o W n K k o w K r D A N y d u t s s h T 7 9 9 5 4 9 9 2 I D M P U Y N y r o t r o b l g n o W n K k o w K r D m r s c p o t 0 0 5 1 s n o s r e v y f f s e g k c p g r o n o t t n e m u c o d r w w w s p t t h 3 0 0 2 l t e y r r z r I e r u d e c o r p A M R e g r e v A y r r t l u M t s u b o R r e h t O c f t n e c S r e h s F o m r e h T 0 4 v e r w t f o S C A T e l o s n o C s s y l n A e m o t p r c s n r T y s s y t l b v l l e c t n e c s e n m u l o l G r e t t l l e C y s s A x e l p 3 2 e n k o t y C e s u o M s e n L l l e C s l e d o M l t n e m r e p x E t d e m o t p r c s n r t x r t e m y f f A t K E P F F A N R K C U Q I t D d e t s o p e D 3 1 L C e s u o M 5 2 L C e s u o M 3 3 O I e s u o M 1 P K H e s u o M C L L e s u o M M M E G m o r f e n l l l e c l f l f 3 5 p r T D 2 1 G s r K e s u o M s e t y c o h p m y l T y r m r p e s u o M J m o M 1 m t 1 g R 7 S 9 2 1 6 B 1 g R e s u o M J 6 L B 7 5 C J 6 L B 7 5 C e s u o M e s u o m c n e g s n r t R C T l e m P e s u o M M M E G C 2 1 G L S L S A R K e s u o M s n r t S s m s n g r O s l e d o M l t n e m r e p x E 4 4 v e r w t f o s e g m g n v L S I V I s m h t r o g l A d n e r w t f o S 7 m s r P d G h p r G 0 1 v o J w o l F r e c l s D 3 Cell Rep Author manuscript available PMC 2019 September 03 Choi et al Page 33 t u o b u d e d r v r h c f d c f l w w w p t t h e r u L s e t u t t s n I r e c n C r e b r F n D r e t n e C g n g m I y l m F y s s o c P D m o r l C e s u o M c f t n e c S r e h s F o m r e h T R E I F I T N E D I E C R U O S E C R U O S E R r o T N E G A E R y s s A y r r o r c m x r t e m y f f A g n g m I R M A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t A u t h o r M n u s c r p t Cell Rep Author manuscript available PMC 2019 September 03